Evaluating thresholds of Mac-2 binding protein glycosylation isomer in association with clinical outcomes in patients with cirrhosis.
| Title: | Evaluating thresholds of Mac-2 binding protein glycosylation isomer in association with clinical outcomes in patients with cirrhosis. |
|---|---|
| Authors: | Doan TH; Department of Gastroenterology, Danang Hospital, Danang 50000, Viet Nam.; Nguyen KM; Department of Genetics, Ho Chi Minh University of Science, Ho Chi Minh City 700000, Viet Nam.; Department of Scientific Affairs, Sysmex Vietnam, Ho Chi Minh City 700000, Viet Nam.; Nguyen XV; Department of Gastroenterology, Danang Hospital, Danang 50000, Viet Nam.; Pham ATN; Department of Laboratory, Danang Hospital, Danang 50000, Viet Nam.; Le ND; Intensive Care Unit, Danang Hospital, Danang 50000, Viet Nam. drnhandanang@gmail.com. |
| Source: | World journal of hepatology [World J Hepatol] 2025 Sep 27; Vol. 17 (9), pp. 109179. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101532469 Publication Model: Print Cited Medium: Print ISSN: 1948-5182 (Print) NLM ISO Abbreviation: World J Hepatol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group; Original Publication: Beijing, China : Baishideng |
| Abstract: | Background: Cirrhosis is a progressive condition characterized by fibrosis that can lead to severe complications and increased mortality. The mac-2 binding protein glycosylation isomer (M2BPGi) is a prominent biomarker for predicting hepatocellular carcinoma (HCC) and cirrhosis-induced esophageal varices (EV).; Aim: To investigate thresholds of M2BPGi associated with HCC, EV, and decompensation in patients with cirrhosis.; Methods: This was a prospective study. A total of 153 patients with cirrhosis who met the inclusion criteria were enrolled. The patients were diagnosed with HCC and EV according to the Baveno VII and European Association for the Study of the Liver guidelines. Baseline serum M2BPGi levels were assessed along with other routine tests. The data analysis aimed to determine the cutoff values of M2BPGi for predicting EV and HCC.; Results: In the study 85.6% of patients were Child-Pugh B and C. M2BPGi mean cutoff index was 7.1 ± 3.7, showing no significant etiological differences. However, M2BPGi levels varied significantly among Child-Pugh classes, EV classifications, and between patients with and without HCC (P < 0.01). M2BPGi cutoff values for predicting HCC, EV, and decompensated cirrhosis were 6.50, 6.64, and 5.25, respectively. Multivariate analysis confirmed M2BPGi as an independent risk factor for EV [adjusted odds ratio (aOR): 1.3, 95%CI: 1.08-1.64] and liver decompensation (aOR: 2.11, 95%CI: 1.37-3.83). Area under the curve of M2BPGi for HCC differentiation was 0.71. An algorithm combining alpha-fetoprotein (AFP) and M2BPGi detected 26 of 28 HCC cases with 98.04% accuracy vs 10 cases by AFP alone.; Conclusion: Serum M2BPGi predicted cirrhosis complications, including decompensation and varices, especially in HCC. Combined with AFP, it enhanced HCC detection. Future liver biopsy studies are needed for tissue confirmation.; (©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Competing Interests: | Conflict-of-interest statement: Khue Minh Nguyen is a Sysmex employee. All other authors declare no conflicts of interest. |
| References: | Dig Dis Sci. 2023 Dec;68(12):4407-4417. (PMID: 37861877); PLoS One. 2021 Oct 14;16(10):e0258589. (PMID: 34648567); Hepatology. 2018 Aug;68(2):723-750. (PMID: 29624699); J Hepatol. 2018 Aug;69(2):406-460. (PMID: 29653741); Ultrasound Med Biol. 2015 May;41(5):1126-47. (PMID: 25805059); Hepatol Commun. 2019 Feb 08;3(4):493-503. (PMID: 30976740); Liver Int. 2016 Feb;36(2):240-5. (PMID: 26212020); Liver Cancer. 2020 Apr;9(2):207-220. (PMID: 32399434); Ann Lab Med. 2021 Jan;41(1):16-24. (PMID: 32829576); Sci Rep. 2013;3:1065. (PMID: 23323209); Sci Rep. 2017 Oct 30;7(1):14352. (PMID: 29085039); Hepatol Res. 2015 Nov;45(11):1083-90. (PMID: 25565570); Dig Endosc. 2010 Jan;22(1):1-9. (PMID: 20078657); J Gastroenterol Hepatol. 2018 Feb 22;:. (PMID: 29473206); J Gastroenterol. 2018 Jul;53(7):819-826. (PMID: 29318378); J Dig Dis. 2018 Apr;19(4):242-253. (PMID: 29607614); Lancet Reg Health Eur. 2021 Nov 04;12:100240. (PMID: 34901909); Ann Hepatol. 2020 Jul - Aug;19(4):367-372. (PMID: 32444247); Liver Cancer. 2024 Aug 14;14(1):68-79. (PMID: 40144467); J Gastroenterol Hepatol. 2018 Nov;33(11):1889-1896. (PMID: 29737582); Expert Rev Proteomics. 2015;12(6):683-93. (PMID: 26394846); Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. (PMID: 31981519); Dig Dis Sci. 1991 Jul;36(7):962-72. (PMID: 1649041); J Infect Dis. 2020 Feb 3;221(4):589-597. (PMID: 31574141); Hepatol Commun. 2023 Nov 8;7(11):. (PMID: 37938100); Gastroenterology. 2018 May;154(6):1706-1718.e1. (PMID: 29425931) |
| Contributed Indexing: | Keywords: Cirrhosis; Esophageal varices; Hepatocellular carcinoma; High-risk esophageal varices; Liver decompensation; Mac-2 binding protein glycosylation isomer |
| Entry Date(s): | Date Created: 20250930 Date Completed: 20250930 Latest Revision: 20251002 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12476715 |
| DOI: | 10.4254/wjh.v17.i9.109179 |
| PMID: | 41024878 |
| Database: | MEDLINE |
Journal Article